NCT04338360Approved For Marketing不适用
Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19
适应症
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 发起方
- Mayo Clinic
- 试验地点
- 12
研究概览
简要总结
This expanded access program will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age at least 18 years
- •Laboratory confirmed diagnosis of infection with SARS-CoV-2
- •Admitted to an acute care facility for the treatment of COVID-19 complications
- •Severe or life threatening COVID-19, or judged by the treating provider to be at high risk of progression to severe or life-threatening disease
- •Informed consent provided by the patient or healthcare proxy
- •Severe COVID-19 is defined by one or more of the following:
- •respiratory frequency ≥ 30/min
- •blood oxygen saturation ≤ 93%
- •partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300
- •lung infiltrates > 50% within 24 to 48 hours
- •Life-threatening COVID-19 is defined as one or more of the following:
- •respiratory failure
- •septic shock
- •multiple organ dysfunction or failure
排除标准
- 未提供
研究者
Michael J. Joyner, M.D.
Principal Investigator
Mayo Clinic
研究点 (12)
Loading locations...
相似试验
No Longer Available
不适用
Expanded Access to Convalescent Plasma for Treatment of COVID-19COVID-19NCT04472572Hackensack Meridian Health
No Longer Available
不适用
Convalescent Plasma for the Treatment of Patients With COVID-19COVID-19SARS-CoV 2NCT04372368University of Colorado, Denver
No Longer Available
不适用
Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 PatientsCOVID-19SARS-CoV 2SARS-CoV InfectionNCT04420988Rutgers, The State University of New Jersey
撤回
3 期
Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 InfectionCovid19NCT06084351Larkin Community Hospital
已完成
2 期
Convalescent Plasma for the Treatment of COVID-19COVID-19NCT04389710Thomas Jefferson University52